NCT03111732View on ClinicalTrials.gov

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

July 22, 2020

Study Completion Date

November 8, 2021

Conditions
Biliary Tract NeoplasmsCholangiocarcinomaBile Duct CancerLiver CancerGallbladder Cancer
Interventions
BIOLOGICAL

Pembrolizumab (MK-3475)

200 mg will be administered as an IV infusion on Day 1 of each 21 day cycle

DRUG

Oxaliplatin

130mg/m(2) IV Infusion will be administered as an IV infusion on Day 1 of cycles 1-6

DRUG

Capecitabine

750 mg/m(2) will be administered orally twice a day on Days 1-14 of cycles 1-6

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03111732 - Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) | Biotech Hunter | Biotech Hunter